No document available.
Abstract :
[en] Snakebite is classified as a Category A neglected tropical disease by the WHO, as it causes the death of about 150,000 people every year, mostly in rural and poor areas of the world. Snake envenoming is classically treated by injecting antivenom, which is antitoxin antibodies (Igs) collected from immunized animals. However, these treatments may induce immunological reactions including severe adverse reaction to the patient. Moreover, venom compositions strongly differ from species, gender and habitat, explaining why providing broadly effective antivenoms is a real challenge.
In this context, quantitatively evaluating the toxin-binding capability of any antivenom is crucial to improve the production of effective snakebite therapeutics.
In this study, we propose an alternative methodology for the so-called ¿antivenomics¿ methodology. Indeed, affinity columns coupled to mass spectrometry have been demonstrated performant, but their preparation and their lifetime represent constraints to the throughput of antivenom evaluation. In this work, we exploit the potential of magnetic beads, LC-MS and shotgun proteomics mass spectrometry to speed up antivenom efficacy characterization. The antivenom Igs are bound to magnetic beads, before being incubated in the presence of various venoms. Comparative MS analysis of the toxins remaining in suspension (not recognized by Ig) and those remaining on the beads (recognized by Ig) allows the binding selectivity of the antivenom to be determined. The strategy is demonstrated here with venom from the medically important African viper, Echis ocellatus.